Get started
Author

Michela Febbraro

Observed names: Febbraro, Michela, M. Febbraro
Observed institutions: University of Ottawa, Juravinski Cancer Centre, Ottawa Hospital, Sault Area Hospital, Hamilton Health Sciences, NOSM University, McMaster University
ORCID: 0000-0002-9155-7773
Observed ORCID: 0000-0002-9155-7773
OpenAlex ID: A5002523264
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
2022 · Hamid Mithoowani, Michela Febbraro · Current Oncology · 290
PDF
The importance of hydrophobic moieties in ice recrystallization inhibitors
2013 · Anna K. Balcerzak, Michela Febbraro, et al. · RSC Advances · 56
Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
2022 · Arani Sathiyapalan, Michela Febbraro, et al. · Current Oncology · 35
PDF
A Retrospective Review of Cancer Treatments and Outcomes among Inuit Referred from Nunavut, Canada
2015 · T.R. Asmis, M. Febbraro, et al. · Current Oncology · 29
PDF
Access to Cancer Care in Northwestern Ontario—A Population-Based Study Using Administrative Data
2020 · M. Febbraro, M. Conlon, et al. · Current Oncology · 13
PDF
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
2025 · Tess Aalto, Maria Abacan, et al. · Cancer Cell · 9
Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology—A National Questionnaire
2023 · Michela Febbraro, Ghazaleh Kazemi, et al. · Current Oncology · 4
PDF
Immunotherapy‐Related Gastritis in Small Cell Lung Cancer Treatment With Durvalumab—A Case Report
2025 · Marc C. Cavaliere, Silvana Spadafora, et al. · Cancer Reports · 1
PDF
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024
2025 · Jennifer Leigh, Arwa Ahmed, et al. · Current Oncology · 1
Enabling precision therapy through dermatologic prophylaxis: lessons from COCOON
2026 · Saqib Raza Khan, Michela Febbraro, et al. · Journal of Thoracic Disease
Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients: prevalence of variants with decreased activity and chemotherapy outcomes
2026 · Christopher Rosso, Michela Febbraro, et al. · Pharmacogenomics
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36).
2025 · Valsamo Anagnostou, Sara Moore, et al. · Journal of Clinical Oncology
Assessing Access to And Outcomes of Medical Oncology and Radiation Oncology Consultation in Non-Small Cell Lung Cancer Patients: A Population-Based Study Using Administrative Data
2023 · Michela Febbraro, Rosalyn Juergens, et al. · Medical Research Archives
PDF
EP04.01-018 Medical Oncology and Radiation Oncology Consultation in Non-small Cell Lung Cancer (NSCLC). A Population-Based Study Using Administrative Data
2022 · M. Febbraro · Journal of Thoracic Oncology
P45.10 Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis
2021 · M. Febbraro, A. Sathiyapalan, et al. · Journal of Thoracic Oncology
PDF
P48.18 Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
2021 · A. Sathiyapalan, M. Febbraro, et al. · Journal of Thoracic Oncology
PDF
Abstract A10: Using large linked databases to understand cancer care access in northwestern Ontario, Canada
2020 · Michela Febbraro, Michael Conlon, et al. · Cancer Epidemiology Biomarkers & Prevention
A review of the Inuit oncology patients treated at the Ottawa Hospital Cancer Centre.
2013 · Michela Febbraro, Johanna Spaans, et al. · Journal of Clinical Oncology
The use of octreotide scans in the diagnosis and follow-up of neuroendocrine tumors (NETs).
2011 · T. Di Valentin, M. Febbraro, et al. · Journal of Clinical Oncology
Works count: 20
Citation count: 438
H-index: 6
I10-index: 5
Year
Topic
Type